Ro

Cover Block

Field	Value
Name	Ro
Tagline	Telehealth company connecting patients with US-licensed professionals for weight loss, sexual health, hair loss, and more.
Headquarters	New York City, United States
Founded	2017
Stage	Series D+
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology Type	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Funding Label	Series D+
Total Disclosed	~$1.03B

Links

• Website: https://ro.co/
• Press / Newsroom: https://ro.co/press/wegovy-savings-options/
• Corporate Blog: https://ro.co/blog/articles/
• Careers (Lever): https://jobs.lever.co/ro/

What an Investor Needs First

Ro is a direct-to-patient telehealth company that has built a vertically integrated stack of online consultations, diagnostics, labs, and pharmacy fulfillment. The GLP-1 weight loss wave has put its consumer health franchise at the center of investor attention [Built In NYC, Unknown] [Sacra, Unknown]. Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, the company began with the Roman brand for erectile dysfunction and has since expanded into hair loss, fertility, skincare, and weight management under the Ro Body banner [Wikipedia, Unknown] [Ro, Unknown]. Differentiation rests on owning the full patient journey end-to-end: Ro pairs licensed providers with its own pharmacy and in-home phlebotomy network [Built In NYC, Unknown]. Capitalization is heavy, with roughly $1.03B disclosed across Series C and D rounds led by General Catalyst and ShawSpring [VC News Daily, Unknown] [Tracxn, Unknown]. Recent commercial signals include a March 2026 collaboration with Novo Nordisk that gives cash-pay patients up to $1,200 per year in savings on Wegovy, and the addition of Eli Lilly's Foundayo to the GLP-1 menu [Ro, March 2026] [PR Newswire, Unknown]. Reported GLP-1 revenue of roughly $370M in 2024 suggests the weight loss line is the company's commercial center of gravity [Sacra, Unknown].

Data Accuracy: GREEN -- Confirmed by Ro press releases, VC News Daily, Built In NYC, and Sacra.

Taxonomy Snapshot

Axis	Value
Stage	Series D+
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech / Telehealth
Technology Type	Software (Non-AI)
Geography	North America (United States)
Growth Profile	Venture Scale
Funding	~$1.03B disclosed across Series C and Series D rounds

Inside the Company

Ro was founded in 2017 in New York City by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, initially under the Roman brand focused on men's sexual health [Wikipedia, Unknown] [Initialized Capital, Unknown]. The founding insight was that a meaningful share of consumer health conditions could be diagnosed and managed through a structured online intake plus licensed-provider review [Initialized Capital, Unknown]. From the original ED franchise, the company added hair loss (Roman), then expanded the corporate brand to Ro and built additional verticals in fertility, dermatology, and weight management [Ro, Unknown].

The company is headquartered in New York and offers nationwide telehealth, in-home care, diagnostics, labs, and pharmacy services [Built In NYC, Unknown] [ZoomInfo, Unknown]. Key milestones include the $200M Series C in July 2020 led by General Catalyst, the $500M Series D in March 2021 led by General Catalyst, and a $150M Series D extension in February 2022 led by ShawSpring [Ro, July 27, 2020] [Ro, March 23, 2021] [Tracxn, Unknown]. Recent product milestones include the launch of compounded ED treatments Daily Rise gummies and Sparks, the Ro Body weight loss program, and the March 2026 Novo Nordisk savings collaboration on Wegovy [Wikipedia, Unknown] [PR Newswire, Unknown] [Ro, March 2026]. Margo Georgiadis, formerly CEO of Ancestry.com, joined Ro's board of directors [Wikipedia, Unknown].

Data Accuracy: GREEN -- Confirmed by Ro press releases, Wikipedia, Initialized Capital, and Built In NYC.

Under the Hood

Ro's product surface is a portfolio of condition-specific consumer brands sitting on a shared clinical, pharmacy, and logistics backbone. The company offers treatment for weight loss, sexual health, hair loss, fertility, skincare, and erectile dysfunction, marketed under names that include Roman, Ro Derm, Ro Fertility, and Ro Body [Ro, Unknown]. The Ro Body weight loss program packages GLP-1 medications with lab testing, one-to-one coaching, and personalized provider care, priced at $39 for the first month and as low as $74 per month on an annual prepay [PR Newswire, Unknown] [Ro, Unknown]. In ED, the company has rolled out compounded formulations branded as Daily Rise gummies and Sparks [Wikipedia, Unknown] [Ro, Unknown].

For weight management, the patient flow includes a virtual visit, lab work performed at home, GLP-1 prescription dispensed through Ro's own pharmacy, ongoing coaching, and an insurance concierge [Ro, Unknown]. The March 2026 Novo Nordisk collaboration extends this to cash-pay savings on branded Wegovy, with up to $1,200 per year in savings on the pen and $600 per year on the pill via 3, 6, and 12 month prepaid plans [Ro, March 2026]. Open engineering roles point to a cloud-native infrastructure with Kubernetes workloads, SOC 2, HIPAA, and HITRUST compliance regimes [Built In, Unknown] [Ro, Unknown].

Data Accuracy: GREEN -- Confirmed by Ro website, PR Newswire, and Built In.

Market Research and Opportunity

Sacra reports Ro generated approximately $370M in GLP-1 revenue in 2024, suggesting GLP-1s have moved from a product line to the dominant commercial vector [Sacra, Unknown]. Demand drivers include the shift of branded GLP-1 manufacturers toward direct-to-consumer cash-pay channels, exemplified by Novo Nordisk's collaboration with Ro on Wegovy savings and Eli Lilly making Foundayo available through the platform [Ro, March 2026] [PR Newswire, Unknown]. Clinically, Ro cites average weight loss of 11 to 20 percent over one year for patients on its program [Ro, Unknown].

Metric	Value
Ro GLP-1 revenue, 2024	~$370M
Average 1-year weight loss on Ro program	11-20%
Wegovy pen savings via Novo Nordisk collaboration	up to $1,200 / year
Ro Body membership entry price	$39 first month, $74/mo annual

Data Accuracy: YELLOW -- Sacra revenue figure is single-source; Ro and Novo Nordisk product and pricing data are GREEN.

Competition and Substitutes

Ro competes against a set of DTC telehealth peers, with differentiation resting on owning more of the stack.

Company	Positioning	Stage / Funding
Ro	Multi-category DTC telehealth with owned pharmacy, labs, and in-home care	Series D+, ~$1.03B disclosed
Hims & Hers	Multi-category DTC telehealth, public company	Public (NYSE: HIMS)
Curology	DTC dermatology with custom-compounded skincare	Venture-backed
Musely	DTC dermatology telehealth	Venture-backed
Nurx	DTC telehealth focused on women's health and contraception	Venture-backed

Ro's defensible edge is the combination of owned pharmacy, owned labs operations, and direct collaborations with branded GLP-1 manufacturers. The Novo Nordisk Wegovy savings program and access to Lilly's Foundayo require pharma counterparties to view the platform as a controlled, compliant channel [Ro, March 2026] [PR Newswire, Unknown].

Data Accuracy: YELLOW -- Subject company data confirmed by multiple sources; competitor positioning drawn from category knowledge.

Opportunity

The headline opportunity

Ro aims to become the default consumer front door for chronic, lifestyle, and stigmatized conditions in the U.S. Evidence includes $370M in 2024 GLP-1 revenue [Sacra, Unknown], the Novo Nordisk Wegovy savings collaboration [Ro, March 2026], and the integration of nationwide telehealth, labs, and pharmacy services [Built In NYC, Unknown].

Growth scenarios

Scenario	What happens	Catalyst
Branded GLP-1 channel of record	Ro becomes the primary DTC channel for branded Wegovy, Zepbound, and successor obesity drugs	Expansion of the Novo Nordisk model
Multi-condition membership flywheel	Ro Body membership economics extend across hair, fertility, and dermatology	Cross-sell of existing weight loss patients
Quasi-clinical infrastructure	Ro positions its nationwide labs, pharmacy, and provider network as infrastructure	A second branded pharma partnership

Data Accuracy: YELLOW -- Headline opportunity grounded in GREEN-cited product, partnership, and pricing data; revenue scale anchored by single-source Sacra figure.

Sources

1. [Ro, Unknown] Ro - Weight loss, better sex, fuller hair, improved skin and more online | https://ro.co/
2. [Ro, Unknown] Ro - Telehealth for ED, Hair loss, Skincare, Fertility and More | https://ro.co/contact-us/
3. [Ro, Unknown] Weight Loss - Ro Body Membership | https://ro.co/weight-loss/
4. [Ro, Unknown] Weight Loss Program Pricing | https://ro.co/weight-loss/pricing/
5. [Ro, Unknown] New funding, same mission | https://ro.co/news/new-funding/
6. [Ro, March 2026] Ro Helps Patients Save up to $1,200 Per Year on Wegovy through Collaboration with Novo Nordisk | https://ro.co/press/wegovy-savings-options/
7. [Ro, Unknown] New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials | https://ro.co/press/68-week-outcomes/
8. [Ro, July 27, 2020] Series C announcement | https://ro.co/news/new-funding/
9. [Ro, March 23, 2021] Series D announcement | https://ro.co/news/new-funding/
10. [VC News Daily, Unknown] Ro Completes $500M Series D Funding Round | https://vcnewsdaily.com/ro/venture-capital-funding/hwftfbdwyg
11. [Wikipedia, Unknown] Ro (company) | https://en.wikipedia.org/wiki/Ro_(company)
12. [Built In NYC, Unknown] Ro (Ro.co) NYC Office: Careers, Perks + Culture | https://www.builtinnyc.com/company/ro
13. [Built In, Unknown] Ro (Ro.co) Offices and Career Growth | https://builtin.com/company/ro
14. [ZoomInfo, Unknown] Ro - Overview, News & Similar companies | https://www.zoominfo.com/c/ro/465295896
15. [Dealroom.co, Unknown] Ro Health company information, funding & investors | https://app.dealroom.co/companies/ro_co
16. [Initialized Capital, Unknown] Founder Spotlight: Zachariah Reitano, Ro CEO | https://blog.initialized.com/2023/07/founder-spotlight-zachariah-reitano-ro-ceo/
17. [PR Newswire, Unknown] Ro News and Press Releases | https://www.prnewswire.com/news/ro/
18. [Sacra, Unknown] Ro GLP-1 revenue analysis | https://sacra.com/
19. [Tracxn, Unknown] Ro funding history | https://tracxn.com/
20. [Woman's World, Unknown] Ro Offers Telehealth Including Weight-Loss Medications | https://www.womansworld.com/weight-loss/glp-1/ro-co-weight-loss